ID   PRKDC_HUMAN             Reviewed;        4128 AA.
AC   P78527; P78528; Q13327; Q13337; Q14175; Q59H99; Q7Z611; Q96SE6;
AC   Q9UME3;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 3.
DT   02-NOV-2010, entry version 120.
DE   RecName: Full=DNA-dependent protein kinase catalytic subunit;
DE            Short=DNA-PK catalytic subunit;
DE            Short=DNA-PKcs;
DE            EC=2.7.11.1;
DE   AltName: Full=DNPK1;
DE   AltName: Full=p460;
GN   Name=PRKDC; Synonyms=HYRC, HYRC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Cervix carcinoma;
RX   MEDLINE=95401275; PubMed=7671312; DOI=10.1016/0092-8674(95)90482-4;
RA   Hartley K.O., Gell D., Smith G.C.M., Zhang H., Divecha N.,
RA   Connelly M.A., Admon A., Lees-Miller S.P., Anderson C.W.,
RA   Jackson S.P.;
RT   "DNA-dependent protein kinase catalytic subunit: a relative of
RT   phosphatidylinositol 3-kinase and the ataxia telangiectasia gene
RT   product.";
RL   Cell 82:849-856(1995).
RN   [2]
RP   SEQUENCE REVISION, AND ALTERNATIVE SPLICING.
RA   Gell D., Anderson C.W.;
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-6; ILE-333;
RP   SER-605; MET-680; SER-695; SER-1071; VAL-1314; VAL-1588; HIS-1603;
RP   VAL-2095; GLU-2702; CYS-2899; ASP-3149; SER-3201; GLU-3404; THR-3434;
RP   SER-3459; MET-3562; LEU-3836 AND VAL-3932.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-1689.
RX   MEDLINE=21312114; PubMed=11418067;
RA   Anderson C.W., Dunn J.J., Freimuth P.I., Galloway A.M.,
RA   Allalunis-Turner M.J.;
RT   "Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA
RT   repair-defective, human, glioma-derived cell line M059J.";
RL   Radiat. Res. 156:2-9(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-49.
RX   MEDLINE=97430835; PubMed=9284934;
RA   Ladenburger E.M., Fackelmayer F.O., Hameister H., Knippers R.;
RT   "MCM4 and PRKDC, human genes encoding proteins MCM4 and DNA-PKcs, are
RT   close neighbours located on chromosome 8q12-->q13.";
RL   Cytogenet. Cell Genet. 77:268-270(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1789-2203.
RC   TISSUE=Placenta;
RX   MEDLINE=95365397; PubMed=7638222; DOI=10.1073/pnas.92.16.7515;
RA   Sipley J.D., Menninger J.C., Hartley K.O., Ward D.C., Jackson S.P.,
RA   Anderson C.W.;
RT   "Gene for the catalytic subunit of the human DNA-activated protein
RT   kinase maps to the site of the XRCC7 gene on chromosome 8.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7515-7519(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2255-2335.
RC   TISSUE=Placenta;
RA   Abe M.;
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3199-4128 (ISOFORM 1).
RC   TISSUE=Fetal lung;
RX   MEDLINE=96062265; PubMed=7594449;
RA   Poltoratsky V.P., Shi X., York J.D., Lieber M.R., Carter T.H.;
RT   "Human DNA-activated protein kinase (DNA-PK) is homologous to
RT   phosphatidylinositol kinases.";
RL   J. Immunol. 155:4529-4533(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3250-4128 (ISOFORM 1).
RA   Anderson C.W., Dunn J.J., Freimuth P.I.;
RT   "Sequence of the 3' segment (exons 70-86) of PRKDC, the gene for human
RT   DNA-PKcs.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3372-4128 (ISOFORM 2).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno F.R.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   PHOSPHORYLATION OF HSPCA.
RX   MEDLINE=90008887; PubMed=2507541;
RA   Lees-Miller S.P., Anderson C.W.;
RT   "The human double-stranded DNA-activated protein kinase phosphorylates
RT   the 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal
RT   threonine residues.";
RL   J. Biol. Chem. 264:17275-17280(1989).
RN   [12]
RP   PHOSPHORYLATION OF H1.
RX   PubMed=2247066;
RA   Carter T., Vancurova I., Sun I., Lou W., DeLeon S.;
RT   "A DNA-activated protein kinase from HeLa cell nuclei.";
RL   Mol. Cell. Biol. 10:6460-6471(1990).
RN   [13]
RP   PHOSPHORYLATION OF MYC.
RX   PubMed=1597196; DOI=10.1111/j.1432-1033.1992.tb16964.x;
RA   Iijima S., Teraoka H., Date T., Tsukada K.;
RT   "DNA-activated protein kinase in Raji Burkitt's lymphoma cells.
RT   Phosphorylation of c-Myc oncoprotein.";
RL   Eur. J. Biochem. 206:595-603(1992).
RN   [14]
RP   PHOSPHORYLATION OF SRF.
RX   PubMed=8407951;
RA   Liu S.-H., Ma J.-T., Yueh A.Y., Lees-Miller S.P., Anderson C.W.,
RA   Ng S.-Y.;
RT   "The carboxyl-terminal transactivation domain of human serum response
RT   factor contains DNA-activated protein kinase phosphorylation sites.";
RL   J. Biol. Chem. 268:21147-21154(1993).
RN   [15]
RP   PHOSPHORYLATION OF JUN.
RX   PubMed=8464713; DOI=10.1093/nar/21.5.1289;
RA   Bannister A.J., Gottlieb T.M., Kouzarides T., Jackson S.P.;
RT   "c-Jun is phosphorylated by the DNA-dependent protein kinase in vitro;
RT   definition of the minimal kinase recognition motif.";
RL   Nucleic Acids Res. 21:1289-1295(1993).
RN   [16]
RP   CLEAVAGE BY CASPASE-3.
RX   PubMed=8804412; DOI=10.1016/0014-5793(96)00842-3;
RA   Teraoka H., Yumoto Y., Watanabe F., Tsukada K., Suwa A., Enari M.,
RA   Nagata S.;
RT   "CPP32/Yama/apopain cleaves the catalytic component of DNA-dependent
RT   protein kinase in the holoenzyme.";
RL   FEBS Lett. 393:1-6(1996).
RN   [17]
RP   ALTERNATIVE SPLICING.
RX   MEDLINE=97074683; PubMed=8917110; DOI=10.1016/0378-1119(96)00135-7;
RA   Connelly M.A., Zhang H., Kieleczawa J., Anderson C.W.;
RT   "Alternate splice-site utilization in the gene for the catalytic
RT   subunit of the DNA-activated protein kinase, DNA-PKcs.";
RL   Gene 175:271-273(1996).
RN   [18]
RP   PHOSPHORYLATION OF TP53.
RX   PubMed=9363941; DOI=10.1016/S0092-8674(00)80416-X;
RA   Shieh S.-Y., Ikeda M., Taya Y., Prives C.;
RT   "DNA damage-induced phosphorylation of p53 alleviates inhibition by
RT   MDM2.";
RL   Cell 91:325-334(1997).
RN   [19]
RP   CHARACTERIZATION.
RX   MEDLINE=98040126; PubMed=9372844; DOI=10.1016/S0921-8777(97)00035-9;
RA   Wu X., Lieber M.R.;
RT   "Interaction between DNA-dependent protein kinase and a novel protein,
RT   KIP.";
RL   Mutat. Res. 385:13-20(1997).
RN   [20]
RP   PHOSPHORYLATION OF XRCC6.
RX   PubMed=9362500; DOI=10.1093/emboj/16.22.6874;
RA   Jin S., Weaver D.T.;
RT   "Double-strand break repair by Ku70 requires heterodimerization with
RT   Ku80 and DNA binding functions.";
RL   EMBO J. 16:6874-6885(1997).
RN   [21]
RP   PHOSPHORYLATION OF RFA2.
RX   MEDLINE=97284742; PubMed=9139719; DOI=10.1074/jbc.272.19.12634;
RA   Niu H., Erdjument-Bromage H., Pan Z.-Q., Lee S.-H., Tempst P.,
RA   Hurwitz J.;
RT   "Mapping of amino acid residues in the p34 subunit of human single-
RT   stranded DNA-binding protein phosphorylated by DNA-dependent protein
RT   kinase and Cdc2 kinase in vitro.";
RL   J. Biol. Chem. 272:12634-12641(1997).
RN   [22]
RP   ENZYME REGULATION.
RX   PubMed=9766667;
RA   Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E.,
RA   Abraham R.T.;
RT   "Inhibition of phosphoinositide 3-kinase related kinases by the
RT   radiosensitizing agent wortmannin.";
RL   Cancer Res. 58:4375-4382(1998).
RN   [23]
RP   FUNCTION, INTERACTION WITH C1D, AND MUTAGENESIS OF LEU-1510 AND
RP   1516-GLU-LEU-1517.
RX   PubMed=9679063;
RA   Yavuzer U., Smith G.C.M., Bliss T., Werner D., Jackson S.P.;
RT   "DNA end-independent activation of DNA-PK mediated via association
RT   with the DNA-binding protein C1D.";
RL   Genes Dev. 12:2188-2199(1998).
RN   [24]
RP   INTERACTION WITH ILF3.
RX   PubMed=9442054; DOI=10.1074/jbc.273.4.2136;
RA   Ting N.S.Y., Kao P.N., Chan D.W., Lintott L.G., Lees-Miller S.P.;
RT   "DNA-dependent protein kinase interacts with antigen receptor response
RT   element binding proteins NF90 and NF45.";
RL   J. Biol. Chem. 273:2136-2145(1998).
RN   [25]
RP   DNA-BINDING.
RX   PubMed=9435225; DOI=10.1073/pnas.95.2.525;
RA   Hammarsten O., Chu G.;
RT   "DNA-dependent protein kinase: DNA binding and activation in the
RT   absence of Ku.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:525-530(1998).
RN   [26]
RP   PHOSPHORYLATION OF XRCC5 AND XRCC6.
RX   PubMed=10026262; DOI=10.1021/bi982584b;
RA   Chan D.W., Ye R., Veillette C.J., Lees-Miller S.P.;
RT   "DNA-dependent protein kinase phosphorylation sites in Ku 70/80
RT   heterodimer.";
RL   Biochemistry 38:1819-1828(1999).
RN   [27]
RP   PHOSPHORYLATION OF PARP1.
RX   PubMed=10467406; DOI=10.1038/sj.onc.1202823;
RA   Ariumi Y., Masutani M., Copeland T.D., Mimori T., Sugimura T.,
RA   Shimotohno K., Ueda K., Hatanaka M., Noda M.;
RT   "Suppression of the poly(ADP-ribose) polymerase activity by DNA-
RT   dependent protein kinase in vitro.";
RL   Oncogene 18:4616-4625(1999).
RN   [28]
RP   PHOSPHORYLATION AT THR-2609; SER-2612; THR-2638 AND THR-2647.
RX   MEDLINE=22304649; PubMed=12186630; DOI=10.1042/BJ20020973;
RA   Douglas P., Sapkota G.P., Morrice N., Yu Y., Goodarzi A.A., Merkle D.,
RA   Meek K., Alessi D.R., Lees-Miller S.P.;
RT   "Identification of in vitro and in vivo phosphorylation sites in the
RT   catalytic subunit of the DNA-dependent protein kinase.";
RL   Biochem. J. 368:243-251(2002).
RN   [29]
RP   INTERACTION WITH DCLRE1C.
RX   MEDLINE=21952476; PubMed=11955432; DOI=10.1016/S0092-8674(02)00671-2;
RA   Ma Y., Pannicke U., Schwarz K., Lieber M.R.;
RT   "Hairpin opening and overhang processing by an Artemis/DNA-dependent
RT   protein kinase complex in nonhomologous end joining and V(D)J
RT   recombination.";
RL   Cell 108:781-794(2002).
RN   [30]
RP   PHOSPHORYLATION OF XRCC4.
RX   MEDLINE=22397538; PubMed=12509254; DOI=10.1016/S1568-7864(01)00018-0;
RA   Hsu H.-L., Yannone S.M., Chen D.J.;
RT   "Defining interactions between DNA-PK and ligase IV/XRCC4.";
RL   DNA Repair 1:225-235(2002).
RN   [31]
RP   MASS SPECTROMETRY, PHOSPHORYLATION AT THR-2609, MUTAGENESIS OF
RP   THR-2609, AND SUBCELLULAR LOCATION.
RX   PubMed=12231622; DOI=10.1101/gad.1015202;
RA   Chan D.W., Chen B.P., Prithivirajsingh S., Kurimasa A., Story M.D.,
RA   Qin J., Chen D.J.;
RT   "Autophosphorylation of the DNA-dependent protein kinase catalytic
RT   subunit is required for rejoining of DNA double-strand breaks.";
RL   Genes Dev. 16:2333-2338(2002).
RN   [32]
RP   PHOSPHORYLATION OF WRN.
RX   PubMed=11889123; DOI=10.1074/jbc.M111523200;
RA   Karmakar P., Piotrowski J., Brosh R.M. Jr., Sommers J.A., Miller S.P.,
RA   Cheng W.H., Snowden C.M., Ramsden D.A., Bohr V.A.;
RT   "Werner protein is a target of DNA-dependent protein kinase in vivo
RT   and in vitro, and its catalytic activities are regulated by
RT   phosphorylation.";
RL   J. Biol. Chem. 277:18291-18302(2002).
RN   [33]
RP   FUNCTION, AND MUTAGENESIS OF THR-2638 AND THR-2647.
RX   PubMed=12649176;
RA   Soubeyrand S., Pope L., Pakuts B., Hache R.J.;
RT   "Threonines 2638/2647 in DNA-PK are essential for cellular resistance
RT   to ionizing radiation.";
RL   Cancer Res. 63:1198-1201(2003).
RN   [34]
RP   PHOSPHORYLATION OF POU2F1.
RX   PubMed=14612514;
RA   Schild-Poulter C., Shih A., Yarymowich N.C., Hache R.J.G.;
RT   "Down-regulation of histone H2B by DNA-dependent protein kinase in
RT   response to DNA damage through modulation of octamer transcription
RT   factor 1.";
RL   Cancer Res. 63:7197-7205(2003).
RN   [35]
RP   PHOSPHORYLATION OF H2AFX.
RX   PubMed=14627815; DOI=10.1093/nar/gkg921;
RA   Park E.-J., Chan D.W., Park J.-H., Oettinger M.A., Kwon J.;
RT   "DNA-PK is activated by nucleosomes and phosphorylates H2AX within the
RT   nucleosomes in an acetylation-dependent manner.";
RL   Nucleic Acids Res. 31:6819-6827(2003).
RN   [36]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15071507; DOI=10.1038/sj.emboj.7600206;
RA   Pannicke U., Ma Y., Hopfner K.-P., Niewolik D., Lieber M.R.,
RA   Schwarz K.;
RT   "Functional and biochemical dissection of the structure-specific
RT   nuclease ARTEMIS.";
RL   EMBO J. 23:1987-1997(2004).
RN   [37]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=14744996; DOI=10.1084/jem.20031142;
RA   Poinsignon C., Moshous D., Callebaut I., de Chasseval R., Villey I.,
RA   de Villartay J.-P.;
RT   "The metallo-beta-lactamase/beta-CASP domain of Artemis constitutes
RT   the catalytic core for V(D)J recombination.";
RL   J. Exp. Med. 199:315-321(2004).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH DCLRE1C.
RX   PubMed=15574326; DOI=10.1016/j.molcel.2004.11.017;
RA   Ma Y., Lu H., Tippin B., Goodman M.F., Shimazaki N., Koiwai O.,
RA   Hsieh C.-L., Schwarz K., Lieber M.R.;
RT   "A biochemically defined system for mammalian nonhomologous DNA end
RT   joining.";
RL   Mol. Cell 16:701-713(2004).
RN   [39]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15456891; DOI=10.1128/MCB.24.20.9207-9220.2004;
RA   Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D.,
RA   Legerski R.J.;
RT   "Artemis is a phosphorylation target of ATM and ATR and is involved in
RT   the G2/M DNA damage checkpoint response.";
RL   Mol. Cell. Biol. 24:9207-9220(2004).
RN   [40]
RP   PHOSPHORYLATION OF DHX9.
RX   PubMed=14704337; DOI=10.1093/nar/gkg933;
RA   Zhang S., Schlott B., Goerlach M., Grosse F.;
RT   "DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA
RT   helicase II/RNA helicase A and hnRNP proteins in an RNA-dependent
RT   manner.";
RL   Nucleic Acids Res. 32:1-10(2004).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [42]
RP   PHOSPHORYLATION OF H2AFX.
RX   PubMed=16046194; DOI=10.1016/j.dnarep.2005.06.005;
RA   Reitsema T., Klokov D., Banath J.P., Olive P.L.;
RT   "DNA-PK is responsible for enhanced phosphorylation of histone H2AX
RT   under hypertonic conditions.";
RL   DNA Repair 4:1172-1181(2005).
RN   [43]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15811628; DOI=10.1016/j.dnarep.2005.02.001;
RA   Wang J., Pluth J.M., Cooper P.K., Cowan M.J., Chen D.J., Yannone S.M.;
RT   "Artemis deficiency confers a DNA double-strand break repair defect
RT   and Artemis phosphorylation status is altered by DNA damage and cell
RT   cycle progression.";
RL   DNA Repair 4:556-570(2005).
RN   [44]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15936993; DOI=10.1016/j.dnarep.2005.04.013;
RA   Ma Y., Schwarz K., Lieber M.R.;
RT   "The Artemis:DNA-PKcs endonuclease cleaves DNA loops, flaps, and
RT   gaps.";
RL   DNA Repair 4:845-851(2005).
RN   [45]
RP   INTERACTION WITH XRCC5.
RX   PubMed=15758953; DOI=10.1038/nature03442;
RA   Falck J., Coates J., Jackson S.P.;
RT   "Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of
RT   DNA damage.";
RL   Nature 434:605-611(2005).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [47]
RP   PHOSPHORYLATION OF XRCC1.
RX   PubMed=16397295; DOI=10.1093/nar/gkj409;
RA   Levy N., Martz A., Bresson A., Spenlehauer C., de Murcia G.,
RA   Menissier-de Murcia J.;
RT   "XRCC1 is phosphorylated by DNA-dependent protein kinase in response
RT   to DNA damage.";
RL   Nucleic Acids Res. 34:32-41(2006).
RN   [48]
RP   REVIEW.
RX   PubMed=15592499; DOI=10.1038/sj.onc.1208332;
RA   Collis S.J., DeWeese T.L., Jeggo P.A., Parker A.R.;
RT   "The life and death of DNA-PK.";
RL   Oncogene 24:949-961(2005).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-2603; THR-2609;
RP   SER-2612; THR-2638; THR-2647 AND THR-2649, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix adenocarcinoma;
RX   PubMed=16565220; DOI=10.1073/pnas.0507066103;
RA   Nousiainen M., Sillje H.H.W., Sauer G., Nigg E.A., Koerner R.;
RT   "Phosphoproteome analysis of the human mitotic spindle.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5391-5396(2006).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-2743, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2612; THR-2638 AND
RP   THR-2647, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1052; SER-2117; SER-3205
RP   AND SER-4026, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [53]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-893; SER-3205 AND
RP   SER-4026, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [54]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [55]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511; SER-841; SER-893;
RP   SER-2612; THR-2671; SER-2672; SER-3205 AND SER-4026, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [57]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [58]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-117; LYS-254; LYS-828;
RP   LYS-832; LYS-1057; LYS-1209; LYS-1970; LYS-2259; LYS-3241; LYS-3260;
RP   LYS-3608; LYS-3621; LYS-3638 AND LYS-3642, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [59]
RP   INTERACTION WITH TELO2 AND TTI1.
RX   PubMed=20427287; DOI=10.1074/jbc.M110.121699;
RA   Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K.,
RA   Iemura S., Natsume T., Mizushima N.;
RT   "Tti1 and Tel2 are critical factors in mammalian target of rapamycin
RT   complex assembly.";
RL   J. Biol. Chem. 285:20109-20116(2010).
RN   [60]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-6; ASN-263; ILE-333; ILE-420;
RP   SER-500; SER-605; LEU-649; SER-695; HIS-1136; VAL-1190; THR-1237;
RP   PHE-1279; MET-1447; GLY-1619; VAL-1680; VAL-1680; PRO-2023; GLN-2598;
RP   ASN-2810; CYS-2899; ALA-2941; ASP-3085; ASP-3149; SER-3198; SER-3201;
RP   GLU-3404; THR-3434; MET-3562; PHE-3584; ILE-3800; LEU-3836; SER-3936
RP   AND MET-3937.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts as a molecular
CC       sensor for DNA damage. Involved in DNA nonhomologous end joining
CC       (NHEJ) required for double-strand break (DSB) repair and V(D)J
CC       recombination. Must be bound to DNA to express its catalytic
CC       properties. Promotes processing of hairpin DNA structures in V(D)J
CC       recombination by activation of the hairpin endonuclease artemis
CC       (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also
CC       required for the NHEJ ligation step. Required to protect and align
CC       broken ends of DNA. May also act as a scaffold protein to aid the
CC       localization of DNA repair proteins to the site of damage. Found
CC       at the ends of chromosomes, suggesting a further role in the
CC       maintenance of telomeric stability and the prevention of
CC       chromosomal end fusion. Also involved in modulation of
CC       transcription. Recognizes the substrate consensus sequence [ST]-Q.
CC       Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby
CC       regulating DNA damage response mechanism. Phosphorylates DCLRE1C,
CC       c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1,
CC       DHX9, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2.
CC       Can phosphorylate C1D not only in the presence of linear DNA but
CC       also in the presence of supercoiled DNA. Ability to phosphorylate
CC       TP53/p53 in the presence of supercoiled DNA is dependent on C1D.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Inhibited by wortmannin. Activity of the enzyme
CC       seems to be attenuated by autophosphorylation.
CC   -!- SUBUNIT: DNA-PK is a heterotrimer of PRKDC and the Ku p70-p86
CC       (XRCC6-XRCC5) dimer. Formation of this complex may be promoted by
CC       interaction with ILF3. Associates with the DNA-bound Ku
CC       heterodimer, but it can also bind to and be activated by free DNA.
CC       Interacts with DNA-PKcs-interacting protein (KIP) with the region
CC       upstream the kinase domain. PRKDC alone also interacts with and
CC       phosphorylates DCLRE1C, thereby activating the latent endonuclease
CC       activity of this protein. Interacts with C1D. Interacts with TTI1
CC       and TELO2.
CC   -!- INTERACTION:
CC       O43918:AIRE; NbExp=1; IntAct=EBI-352053, EBI-1753081;
CC       P42575:CASP2; NbExp=2; IntAct=EBI-352053, EBI-520342;
CC       P09629:HOXB7; NbExp=1; IntAct=EBI-352053, EBI-1248457;
CC       Q9HB75:LRDD; NbExp=5; IntAct=EBI-352053, EBI-520427;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P78527-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P78527-2; Sequence=VSP_004708;
CC   -!- PTM: Phosphorylated upon DNA damage, probably by ATM or ATR.
CC       Autophosphorylated on Thr-2609, Thr-2638 and Thr-2647. Thr-2609 is
CC       a DNA damage-inducible phosphorylation site (inducible with
CC       ionizing radiation, IR). Autophosphorylation induces a
CC       conformational change that leads to remodeling of the DNA-PK
CC       complex, requisite for efficient end processing and DNA repair.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family.
CC   -!- SIMILARITY: Contains 1 FAT domain.
CC   -!- SIMILARITY: Contains 1 FATC domain.
CC   -!- SIMILARITY: Contains 2 HEAT repeats.
CC   -!- SIMILARITY: Contains 1 PI3K/PI4K domain.
CC   -!- SIMILARITY: Contains 3 TPR repeats.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/prkdc/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U47077; AAB39925.5; -; mRNA.
DR   EMBL; U34994; AAC50210.3; -; mRNA.
DR   EMBL; AY316117; AAP69525.1; -; Genomic_DNA.
DR   EMBL; U63630; AAC52019.2; -; Genomic_DNA.
DR   EMBL; U90415; AAB51722.1; -; Genomic_DNA.
DR   EMBL; L27425; AAA79244.1; -; Genomic_DNA.
DR   EMBL; AB052953; BAB79635.1; -; Genomic_DNA.
DR   EMBL; U35835; AAA79184.1; -; mRNA.
DR   EMBL; AY030284; AAK40350.1; -; Genomic_DNA.
DR   EMBL; AB208860; BAD92097.1; -; mRNA.
DR   IPI; IPI00296337; -.
DR   IPI; IPI00376215; -.
DR   PIR; A57099; A57099.
DR   PIR; G02083; G02083.
DR   RefSeq; NP_001075109.1; -.
DR   RefSeq; NP_008835.5; -.
DR   UniGene; Hs.491682; -.
DR   ProteinModelPortal; P78527; -.
DR   SMR; P78527; 3716-4006.
DR   DIP; DIP-24186N; -.
DR   IntAct; P78527; 78.
DR   MINT; MINT-5006046; -.
DR   STRING; P78527; -.
DR   PhosphoSite; P78527; -.
DR   SWISS-2DPAGE; P78527; -.
DR   PRIDE; P78527; -.
DR   Ensembl; ENST00000314191; ENSP00000313420; ENSG00000121031.
DR   GeneID; 5591; -.
DR   KEGG; hsa:5591; -.
DR   CTD; 5591; -.
DR   GeneCards; GC08M048685; -.
DR   H-InvDB; HIX0017562; -.
DR   HGNC; HGNC:9413; PRKDC.
DR   HPA; CAB005167; -.
DR   MIM; 600899; gene.
DR   PharmGKB; PA33776; -.
DR   eggNOG; prNOG10627; -.
DR   HOVERGEN; HBG053681; -.
DR   InParanoid; P78527; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; bard1pathway; BARD1 signaling events.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; ar_pathway; Coregulation of Androgen receptor activity.
DR   Pathway_Interaction_DB; faspathway; FAS signaling pathway (CD95).
DR   Reactome; REACT_216; DNA Repair.
DR   NextBio; 21692; -.
DR   ArrayExpress; P78527; -.
DR   Bgee; P78527; -.
DR   Genevestigator; P78527; -.
DR   GermOnline; ENSG00000121031; Homo sapiens.
DR   GO; GO:0005958; C:DNA-dependent protein kinase-DNA ligase 4 c...; IDA:MGI.
DR   GO; GO:0005667; C:transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:MGI.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologou...; IEA:InterPro.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0010552; P:positive regulation of gene-specific transc...; IMP:BHF-UCL.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR003152; FATC.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR012582; NUC194.
DR   InterPro; IPR000403; PI3/4_kinase_cat.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   Gene3D; G3DSA:1.25.10.10; ARM-like; 6.
DR   Gene3D; G3DSA:1.10.1070.11; PI3/4_kinase_cat; 3.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF02260; FATC; 1.
DR   Pfam; PF08163; NUC194; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; ARM-type_fold; 3.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS50077; HEAT_REPEAT; FALSE_NEG.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS50005; TPR; FALSE_NEG.
DR   PROSITE; PS50293; TPR_REGION; FALSE_NEG.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Complete proteome;
KW   DNA damage; DNA recombination; DNA repair; DNA-binding; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism; Repeat;
KW   Serine/threonine-protein kinase; TPR repeat; Transferase.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2   4128       DNA-dependent protein kinase catalytic
FT                                subunit.
FT                                /FTId=PRO_0000225598.
FT   REPEAT      288    323       HEAT 1.
FT   REPEAT     1004   1040       HEAT 2.
FT   DOMAIN     1503   1538       Leucine-zipper.
FT   REPEAT     1723   1756       TPR 1.
FT   DOMAIN     2883   3539       FAT.
FT   REPEAT     2920   2948       TPR 2.
FT   REPEAT     2949   2982       TPR 3.
FT   DOMAIN     3747   4015       PI3K/PI4K.
FT   DOMAIN     4096   4128       FATC.
FT   REGION     1503   1538       Interaction with C1D.
FT   REGION     2436   3212       KIP-binding.
FT   SITE       2020   2021       Cleavage; by caspase-3 (Probable).
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES     117    117       N6-acetyllysine.
FT   MOD_RES     254    254       N6-acetyllysine.
FT   MOD_RES     511    511       Phosphoserine.
FT   MOD_RES     828    828       N6-acetyllysine.
FT   MOD_RES     832    832       N6-acetyllysine.
FT   MOD_RES     841    841       Phosphoserine.
FT   MOD_RES     893    893       Phosphoserine.
FT   MOD_RES    1052   1052       Phosphoserine.
FT   MOD_RES    1057   1057       N6-acetyllysine.
FT   MOD_RES    1209   1209       N6-acetyllysine.
FT   MOD_RES    1970   1970       N6-acetyllysine.
FT   MOD_RES    2117   2117       Phosphoserine.
FT   MOD_RES    2259   2259       N6-acetyllysine.
FT   MOD_RES    2603   2603       Phosphothreonine.
FT   MOD_RES    2609   2609       Phosphothreonine; by autocatalysis.
FT   MOD_RES    2612   2612       Phosphoserine; by autocatalysis.
FT   MOD_RES    2638   2638       Phosphothreonine; by autocatalysis.
FT   MOD_RES    2647   2647       Phosphothreonine; by autocatalysis.
FT   MOD_RES    2649   2649       Phosphothreonine.
FT   MOD_RES    2671   2671       Phosphothreonine.
FT   MOD_RES    2672   2672       Phosphoserine.
FT   MOD_RES    2743   2743       Phosphotyrosine.
FT   MOD_RES    3205   3205       Phosphoserine.
FT   MOD_RES    3241   3241       N6-acetyllysine.
FT   MOD_RES    3260   3260       N6-acetyllysine.
FT   MOD_RES    3608   3608       N6-acetyllysine.
FT   MOD_RES    3621   3621       N6-acetyllysine.
FT   MOD_RES    3638   3638       N6-acetyllysine.
FT   MOD_RES    3642   3642       N6-acetyllysine.
FT   MOD_RES    4026   4026       Phosphoserine.
FT   VAR_SEQ    3799   3829       Missing (in isoform 2).
FT                                /FTId=VSP_004708.
FT   VARIANT       6      6       A -> S (in dbSNP:rs8177999).
FT                                /FTId=VAR_019179.
FT   VARIANT     263    263       K -> N (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041602.
FT   VARIANT     333    333       M -> I (in dbSNP:rs8178017).
FT                                /FTId=VAR_019180.
FT   VARIANT     420    420       V -> I (in dbSNP:rs55925466).
FT                                /FTId=VAR_041603.
FT   VARIANT     500    500       G -> S (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041604.
FT   VARIANT     605    605       T -> S (in dbSNP:rs8178033).
FT                                /FTId=VAR_019181.
FT   VARIANT     649    649       F -> L (in dbSNP:rs55811715).
FT                                /FTId=VAR_041605.
FT   VARIANT     680    680       I -> M (in dbSNP:rs8178040).
FT                                /FTId=VAR_019182.
FT   VARIANT     695    695       P -> S (in dbSNP:rs8178046).
FT                                /FTId=VAR_019183.
FT   VARIANT    1071   1071       N -> S (in dbSNP:rs8178070).
FT                                /FTId=VAR_019184.
FT   VARIANT    1136   1136       R -> H (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041606.
FT   VARIANT    1190   1190       L -> V (in dbSNP:rs34598508).
FT                                /FTId=VAR_041607.
FT   VARIANT    1237   1237       A -> T.
FT                                /FTId=VAR_041608.
FT   VARIANT    1279   1279       L -> F.
FT                                /FTId=VAR_041609.
FT   VARIANT    1314   1314       G -> V (in dbSNP:rs8178090).
FT                                /FTId=VAR_019185.
FT   VARIANT    1447   1447       R -> M (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041610.
FT   VARIANT    1588   1588       D -> V (in dbSNP:rs8178104).
FT                                /FTId=VAR_019186.
FT   VARIANT    1603   1603       Q -> H (in dbSNP:rs8178106).
FT                                /FTId=VAR_019187.
FT   VARIANT    1619   1619       A -> G (in dbSNP:rs56182356).
FT                                /FTId=VAR_041611.
FT   VARIANT    1680   1680       A -> V (in a metastatic melanoma sample;
FT                                somatic mutation; dbSNP:rs55735910).
FT                                /FTId=VAR_041612.
FT   VARIANT    2023   2023       S -> P (in dbSNP:rs56042895).
FT                                /FTId=VAR_041613.
FT   VARIANT    2095   2095       A -> V (in dbSNP:rs8178147).
FT                                /FTId=VAR_019188.
FT   VARIANT    2598   2598       R -> Q (in dbSNP:rs55923149).
FT                                /FTId=VAR_041614.
FT   VARIANT    2702   2702       K -> E (in dbSNP:rs8178178).
FT                                /FTId=VAR_019189.
FT   VARIANT    2810   2810       S -> N (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041615.
FT   VARIANT    2899   2899       R -> C (in dbSNP:rs4278157).
FT                                /FTId=VAR_019190.
FT   VARIANT    2941   2941       G -> A (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041616.
FT   VARIANT    3085   3085       E -> D (in dbSNP:rs56135402).
FT                                /FTId=VAR_041617.
FT   VARIANT    3149   3149       G -> D (in dbSNP:rs8178208).
FT                                /FTId=VAR_019191.
FT   VARIANT    3198   3198       T -> S (in dbSNP:rs55793951).
FT                                /FTId=VAR_041618.
FT   VARIANT    3201   3201       P -> S (in dbSNP:rs8178216).
FT                                /FTId=VAR_019192.
FT   VARIANT    3404   3404       G -> E (in dbSNP:rs8178225).
FT                                /FTId=VAR_019193.
FT   VARIANT    3434   3434       I -> T (in dbSNP:rs7830743).
FT                                /FTId=VAR_019194.
FT   VARIANT    3459   3459       N -> S (in dbSNP:rs8178228).
FT                                /FTId=VAR_019195.
FT   VARIANT    3562   3562       L -> M (in dbSNP:rs8178232).
FT                                /FTId=VAR_019196.
FT   VARIANT    3584   3584       L -> F.
FT                                /FTId=VAR_041619.
FT   VARIANT    3702   3702       P -> L (in dbSNP:rs8178236).
FT                                /FTId=VAR_050534.
FT   VARIANT    3800   3800       L -> I.
FT                                /FTId=VAR_041620.
FT   VARIANT    3836   3836       P -> L (in dbSNP:rs8178245).
FT                                /FTId=VAR_019197.
FT   VARIANT    3932   3932       M -> V.
FT                                /FTId=VAR_019198.
FT   VARIANT    3936   3936       G -> S.
FT                                /FTId=VAR_041621.
FT   VARIANT    3937   3937       V -> M.
FT                                /FTId=VAR_041622.
FT   MUTAGEN    1510   1510       L->P: Loss of interaction with C1D.
FT   MUTAGEN    1516   1517       EL->PD: Loss of interaction with C1D.
FT   MUTAGEN    2609   2609       T->A: Leads to radiation sensitivity and
FT                                impaired DSB joining. Gives rise to
FT                                reduced phosphorylation; when associated
FT                                with A-2612.
FT   MUTAGEN    2612   2612       S->A: Reduced phosphorylation; when
FT                                associated with A-2609.
FT   MUTAGEN    2638   2638       T->A: Alleviates phosphorylation, leaves
FT                                a fully active enzyme with compromised
FT                                cellular resistance to ionizing radiation
FT                                without affecting DNA end joining; when
FT                                associated with A-2647.
FT   MUTAGEN    2647   2647       T->A: Alleviates phosphorylation, leaves
FT                                a fully active enzyme with compromised
FT                                cellular resistance to ionizing radiation
FT                                without affecting DNA end joining; when
FT                                associated with A-2638.
FT   CONFLICT    405    405       D -> Y (in Ref. 2; AAC50210).
FT   CONFLICT   1008   1008       A -> S (in Ref. 2; AAC50210).
FT   CONFLICT   3660   3660       N -> T (in Ref. 8).
FT   CONFLICT   3817   3817       L -> W (in Ref. 8).
FT   CONFLICT   3862   3862       A -> P (in Ref. 8).
FT   CONFLICT   4031   4031       I -> V (in Ref. 9).
SQ   SEQUENCE   4128 AA;  469089 MW;  AC6E747FEB09F3E5 CRC64;
     MAGSGAGVRC SLLRLQETLS AADRCGAALA GHQLIRGLGQ ECVLSSSPAV LALQTSLVFS
     RDFGLLVFVR KSLNSIEFRE CREEILKFLC IFLEKMGQKI APYSVEIKNT CTSVYTKDRA
     AKCKIPALDL LIKLLQTFRS SRLMDEFKIG ELFSKFYGEL ALKKKIPDTV LEKVYELLGL
     LGEVHPSEMI NNAENLFRAF LGELKTQMTS AVREPKLPVL AGCLKGLSSL LCNFTKSMEE
     DPQTSREIFN FVLKAIRPQI DLKRYAVPSA GLRLFALHAS QFSTCLLDNY VSLFEVLLKW
     CAHTNVELKK AALSALESFL KQVSNMVAKN AEMHKNKLQY FMEQFYGIIR NVDSNNKELS
     IAIRGYGLFA GPCKVINAKD VDFMYVELIQ RCKQMFLTQT DTGDDRVYQM PSFLQSVASV
     LLYLDTVPEV YTPVLEHLVV MQIDSFPQYS PKMQLVCCRA IVKVFLALAA KGPVLRNCIS
     TVVHQGLIRI CSKPVVLPKG PESESEDHRA SGEVRTGKWK VPTYKDYVDL FRHLLSSDQM
     MDSILADEAF FSVNSSSESL NHLLYDEFVK SVLKIVEKLD LTLEIQTVGE QENGDEAPGV
     WMIPTSDPAA NLHPAKPKDF SAFINLVEFC REILPEKQAE FFEPWVYSFS YELILQSTRL
     PLISGFYKLL SITVRNAKKI KYFEGVSPKS LKHSPEDPEK YSCFALFVKF GKEVAVKMKQ
     YKDELLASCL TFLLSLPHNI IELDVRAYVP ALQMAFKLGL SYTPLAEVGL NALEEWSIYI
     DRHVMQPYYK DILPCLDGYL KTSALSDETK NNWEVSALSR AAQKGFNKVV LKHLKKTKNL
     SSNEAISLEE IRIRVVQMLG SLGGQINKNL LTVTSSDEMM KSYVAWDREK RLSFAVPFRE
     MKPVIFLDVF LPRVTELALT ASDRQTKVAA CELLHSMVMF MLGKATQMPE GGQGAPPMYQ
     LYKRTFPVLL RLACDVDQVT RQLYEPLVMQ LIHWFTNNKK FESQDTVALL EAILDGIVDP
     VDSTLRDFCG RCIREFLKWS IKQITPQQQE KSPVNTKSLF KRLYSLALHP NAFKRLGASL
     AFNNIYREFR EEESLVEQFV FEALVIYMES LALAHADEKS LGTIQQCCDA IDHLCRIIEK
     KHVSLNKAKK RRLPRGFPPS ASLCLLDLVK WLLAHCGRPQ TECRHKSIEL FYKFVPLLPG
     NRSPNLWLKD VLKEEGVSFL INTFEGGGCG QPSGILAQPT LLYLRGPFSL QATLCWLDLL
     LAALECYNTF IGERTVGALQ VLGTEAQSSL LKAVAFFLES IAMHDIIAAE KCFGTGAAGN
     RTSPQEGERY NYSKCTVVVR IMEFTTTLLN TSPEGWKLLK KDLCNTHLMR VLVQTLCEPA
     SIGFNIGDVQ VMAHLPDVCV NLMKALKMSP YKDILETHLR EKITAQSIEE LCAVNLYGPD
     AQVDRSRLAA VVSACKQLHR AGLLHNILPS QSTDLHHSVG TELLSLVYKG IAPGDERQCL
     PSLDLSCKQL ASGLLELAFA FGGLCERLVS LLLNPAVLST ASLGSSQGSV IHFSHGEYFY
     SLFSETINTE LLKNLDLAVL ELMQSSVDNT KMVSAVLNGM LDQSFRERAN QKHQGLKLAT
     TILQHWKKCD SWWAKDSPLE TKMAVLALLA KILQIDSSVS FNTSHGSFPE VFTTYISLLA
     DTKLDLHLKG QAVTLLPFFT SLTGGSLEEL RRVLEQLIVA HFPMQSREFP PGTPRFNNYV
     DCMKKFLDAL ELSQSPMLLE LMTEVLCREQ QHVMEELFQS SFRRIARRGS CVTQVGLLES
     VYEMFRKDDP RLSFTRQSFV DRSLLTLLWH CSLDALREFF STIVVDAIDV LKSRFTKLNE
     STFDTQITKK MGYYKILDVM YSRLPKDDVH AKESKINQVF HGSCITEGNE LTKTLIKLCY
     DAFTENMAGE NQLLERRRLY HCAAYNCAIS VICCVFNELK FYQGFLFSEK PEKNLLIFEN
     LIDLKRRYNF PVEVEVPMER KKKYIEIRKE AREAANGDSD GPSYMSSLSY LADSTLSEEM
     SQFDFSTGVQ SYSYSSQDPR PATGRFRRRE QRDPTVHDDV LELEMDELNR HECMAPLTAL
     VKHMHRSLGP PQGEEDSVPR DLPSWMKFLH GKLGNPIVPL NIRLFLAKLV INTEEVFRPY
     AKHWLSPLLQ LAASENNGGE GIHYMVVEIV ATILSWTGLA TPTGVPKDEV LANRLLNFLM
     KHVFHPKRAV FRHNLEIIKT LVECWKDCLS IPYRLIFEKF SGKDPNSKDN SVGIQLLGIV
     MANDLPPYDP QCGIQSSEYF QALVNNMSFV RYKEVYAAAA EVLGLILRYV MERKNILEES
     LCELVAKQLK QHQNTMEDKF IVCLNKVTKS FPPLADRFMN AVFFLLPKFH GVLKTLCLEV
     VLCRVEGMTE LYFQLKSKDF VQVMRHRDDE RQKVCLDIIY KMMPKLKPVE LRELLNPVVE
     FVSHPSTTCR EQMYNILMWI HDNYRDPESE TDNDSQEIFK LAKDVLIQGL IDENPGLQLI
     IRNFWSHETR LPSNTLDRLL ALNSLYSPKI EVHFLSLATN FLLEMTSMSP DYPNPMFEHP
     LSECEFQEYT IDSDWRFRST VLTPMFVETQ ASQGTLQTRT QEGSLSARWP VAGQIRATQQ
     QHDFTLTQTA DGRSSFDWLT GSSTDPLVDH TSPSSDSLLF AHKRSERLQR APLKSVGPDF
     GKKRLGLPGD EVDNKVKGAA GRTDLLRLRR RFMRDQEKLS LMYARKGVAE QKREKEIKSE
     LKMKQDAQVV LYRSYRHGDL PDIQIKHSSL ITPLQAVAQR DPIIAKQLFS SLFSGILKEM
     DKFKTLSEKN NITQKLLQDF NRFLNTTFSF FPPFVSCIQD ISCQHAALLS LDPAAVSAGC
     LASLQQPVGI RLLEEALLRL LPAELPAKRV RGKARLPPDV LRWVELAKLY RSIGEYDVLR
     GIFTSEIGTK QITQSALLAE ARSDYSEAAK QYDEALNKQD WVDGEPTEAE KDFWELASLD
     CYNHLAEWKS LEYCSTASID SENPPDLNKI WSEPFYQETY LPYMIRSKLK LLLQGEADQS
     LLTFIDKAMH GELQKAILEL HYSQELSLLY LLQDDVDRAK YYIQNGIQSF MQNYSSIDVL
     LHQSRLTKLQ SVQALTEIQE FISFISKQGN LSSQVPLKRL LNTWTNRYPD AKMDPMNIWD
     DIITNRCFFL SKIEEKLTPL PEDNSMNVDQ DGDPSDRMEV QEQEEDISSL IRSCKFSMKM
     KMIDSARKQN NFSLAMKLLK ELHKESKTRD DWLVSWVQSY CRLSHCRSRS QGCSEQVLTV
     LKTVSLLDEN NVSSYLSKNI LAFRDQNILL GTTYRIIANA LSSEPACLAE IEEDKARRIL
     ELSGSSSEDS EKVIAGLYQR AFQHLSEAVQ AAEEEAQPPS WSCGPAAGVI DAYMTLADFC
     DQQLRKEEEN ASVIDSAELQ AYPALVVEKM LKALKLNSNE ARLKFPRLLQ IIERYPEETL
     SLMTKEISSV PCWQFISWIS HMVALLDKDQ AVAVQHSVEE ITDNYPQAIV YPFIISSESY
     SFKDTSTGHK NKEFVARIKS KLDQGGVIQD FINALDQLSN PELLFKDWSN DVRAELAKTP
     VNKKNIEKMY ERMYAALGDP KAPGLGAFRR KFIQTFGKEF DKHFGKGGSK LLRMKLSDFN
     DITNMLLLKM NKDSKPPGNL KECSPWMSDF KVEFLRNELE IPGQYDGRGK PLPEYHVRIA
     GFDERVTVMA SLRRPKRIII RGHDEREHPF LVKGGEDLRQ DQRVEQLFQV MNGILAQDSA
     CSQRALQLRT YSVVPMTSRL GLIEWLENTV TLKDLLLNTM SQEEKAAYLS DPRAPPCEYK
     DWLTKMSGKH DVGAYMLMYK GANRTETVTS FRKRESKVPA DLLKRAFVRM STSPEAFLAL
     RSHFASSHAL ICISHWILGI GDRHLNNFMV AMETGGVIGI DFGHAFGSAT QFLPVPELMP
     FRLTRQFINL MLPMKETGLM YSIMVHALRA FRSDPGLLTN TMDVFVKEPS FDWKNFEQKM
     LKKGGSWIQE INVAEKNWYP RQKICYAKRK LAGANPAVIT CDELLLGHEK APAFRDYVAV
     ARGSKDHNIR AQEPESGLSE ETQVKCLMDQ ATDPNILGRT WEGWEPWM
//
